Causal multi-modal AI for personalized chemosensitivity prediction

📅 2026-09-11
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
本文通过开发一个基于常规病理和临床信息的因果多模态AI模型,解决了乳腺癌化疗敏感性个性化预测的问题,以减少过度化疗。
📝 Abstract
Chemotherapy improves survival for some patients with breast cancer, but doctors cannot reliably predict who. Current guidelines rely on recurrence scores as a proxy for treatment benefit, which may contribute to the overprescription of chemotherapy. Here we present a causal multi-modal AI model that predicts personalized chemosensitivity using routinely collected pathology and clinical information. We developed our model on a multi-national dataset of 9,141 patients (twelve cohorts, nine countries) and evaluated it on another 1,994 patients (five cohorts, three countries). The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons. Moreover, its chemotherapy benefit predictions demonstrated robust predictive performance, and out-performed existing recurrence-score-based tests. Compared to the standard of care, using the model to support personally tailored therapeutic decisions could reduce the number of patients receiving chemotherapy by 30% while achieving the same recurrence-free rate. Tumors predicted to be highly chemosensitive displayed concordant molecular and morphological programs of proliferation, cell cycle progression, and replication stress. The model's predictive capabilities transferred zero-shot to non-breast cancers, indicating our causal multi-modal AI approach may provide a universal strategy to predict treatment outcomes across cancer types.
Problem

Research questions and friction points this paper is trying to address.

chemotherapy
breast cancer
personalized chemosensitivity
recurrence scores
overprescription
Innovation

Methods, ideas, or system contributions that make the work stand out.

causal multi-modal AI
personalized chemosensitivity prediction
zero-shot transfer
treatment-specific recurrence probabilities
robust predictive performance
🔎 Similar Papers
No similar papers found.
D
Dhruva Biswas
Ataraxis AI, New York, NY, USA
Jeroen Berrevoets
Jeroen Berrevoets
University of Cambridge
Machine LearningCausality
A
Alec McClean
Ataraxis AI, New York, NY, USA
L
Linus Bao
Ataraxis AI, New York, NY, USA
Jungkyu Park
Jungkyu Park
New York University
Machine LearningDeep LearningMedical Imaging
K
Ken G. Zeng
Ataraxis AI, New York, NY, USA
J
Joseph Cappadona
Ataraxis AI, New York, NY, USA
C
Cerise Tang
Ataraxis AI, New York, NY, USA
C
Chuwen Liu
Ataraxis AI, New York, NY, USA
B
Bartosz Machura
Ataraxis AI, New York, NY, USA
Yin Wu
Yin Wu
Karlsruher Institut für Technologie
Autonomous DrivingADASScenario ExtractionAnomaly Detection
Valerie Speirs
Valerie Speirs
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK; Aberdeen Cancer Centre, University of Aberdeen, Aberdeen, UK
H
Hatem Soliman
Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
R
Rohit Bhargava
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA; Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA
S
Sheheryar Kabraji
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
T
Thaer Khoury
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
David Page
David Page
Director, Whitehead Institute
B
Brian Piening
Providence Genomics, Portland, OR, USA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
C
Carlo Bifulco
Providence Genomics, Portland, OR, USA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
C
Claudia Meurs
Laboratory of Pathology, Dordrecht, Netherlands
P
Pieter Westenend
Laboratory of Pathology, Dordrecht, Netherlands
S
Sylvie Chabaud
Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France
J
Jerome Lemonnier
R&D Unicancer, Paris, France
P
Paul H. Cottu
Medical Oncology, Institut Curie, Université, Paris, France
F
Florence Dalenc
Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France